<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02057796</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12290</org_study_id>
    <nct_id>NCT02057796</nct_id>
  </id_info>
  <brief_title>Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts &lt;100/mm3</brief_title>
  <acronym>STATIS</acronym>
  <official_title>Systematic Empirical vs. Test-guided Anti-tuberculosis Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating Antiretroviral Therapy With CD4 Cell Counts &lt;100/mm3: the STATIS Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In countries with a high tuberculosis (TB) prevalence, TB and invasive bacterial infections&#xD;
      are leading causes of early death in patients who initiate antiretroviral therapy (ART) with&#xD;
      advanced immunodeficiency.&#xD;
&#xD;
      We hypothesize that a systematic 6-month empirical TB treatment initiated 2 weeks before the&#xD;
      introduction of ART in HIV-infected adults with severe immunosuppression (CD4&lt;100/mm3) and no&#xD;
      overt evidence of TB will reduce the risk of death and invasive bacterial infections. This&#xD;
      strategy will be compared to one of extensive TB testing using point-of-care tests (Xpert&#xD;
      MTB/RIF® and urine lipoarabinomanan LAM) and chest X-ray to identify and treat only patients&#xD;
      with at least one positive test suggestive of TB.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Settings: Cambodia, Côte d'Ivoire, Uganda, Vietnam. Design: Multicentre, two-arm, unblinded&#xD;
      randomized controlled superiority trial.&#xD;
&#xD;
      Objective: To compare the 24-week risk of death and occurrence of invasive bacterial&#xD;
      infection between two experimental strategies in HIV-1 infected adults who start ART with a&#xD;
      CD4 count &lt;100/mm3: (i) continuous extensive TB screening during follow-up each time the&#xD;
      patient present with symptoms, versus (ii) systematic empirical TB treatment started 2 weeks&#xD;
      before ART initiation.&#xD;
&#xD;
      Trial strategies:&#xD;
&#xD;
      At inclusion, participants will be randomized 1:1 in two strategies of TB testing and&#xD;
      treatment: extensive TB screening, or systematic empirical TB treatment.&#xD;
&#xD;
      Extensive TB screening (arm 1): In this arm:&#xD;
&#xD;
        -  TB screening point-of-care tests (Xpert MTB/RIF®, urine LAM) and chest X-ray will be&#xD;
           used extensively at randomisation (in all patients) and during follow-up (in patients&#xD;
           with signs or symptoms suggestive of TB);&#xD;
&#xD;
        -  Only patients who meet standardized criteria for TB at inclusion or during follow-up&#xD;
           will receive a standard TB treatment (2ERHZ/4RH);&#xD;
&#xD;
        -  ART (tenofovir(TDF)-lamivudine (3TC)/emtricitabine(FTC) or zidovudine (AZT)-lamivudine+&#xD;
           efavirenz) will be started immediately after randomization in patients not put on TB&#xD;
           treatment, and 2 weeks after initiation of TB treatment in others.&#xD;
&#xD;
      Systematic empirical TB treatment (arm 2): In this arm:&#xD;
&#xD;
        -  TB screening point-of-care tests will not be used;&#xD;
&#xD;
        -  All patients will start a 6-month standard TB treatment (2ERHZ/4RH) at randomization;&#xD;
           ART (tenofovir-lamivudine/emtricitabine or zidovudine-lamivudine+ efavirenz) will be&#xD;
           started 2 weeks after TB treatment initiation.&#xD;
&#xD;
      Both strategies will apply to the first 24 weeks in the trial (intervention period).&#xD;
&#xD;
      From week-24 to week-48, the choice of TB tests and the prescription of TB treatment will be&#xD;
      left upon the decision of the investigator in both trial arms.&#xD;
&#xD;
      Inclusion time: 24 months. Follow-up: each patient will be followed 48 weeks. Statistical&#xD;
      analysis: the primary analysis will be intention to treat. It will compare the 24-week&#xD;
      probability of death or invasive bacterial infection between arms.&#xD;
&#xD;
      Sample size: 1050 participants. This will allow demonstration of a 40% reduction in the&#xD;
      24-week probability of death or invasive bacterial infection in arm 2, compared to arm 1 (α&#xD;
      5%; 1-β 80%).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality and incidence of invasive bacterial infections</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary endpoint is the composite of (i) 24-week all-cause mortality and (ii) 24-week incidence of invasive bacterial infections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of confirmed/probable/possible TB</measure>
    <time_frame>24 Weeks and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3 or 4 adverse events</measure>
    <time_frame>24 Weeks and 48 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of TB-associated IRIS</measure>
    <time_frame>24 Weeks and 48 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of AIDS-defining diseases other than TB</measure>
    <time_frame>24 Weeks and 48 Weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1050</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Xpert MTB/RIF®, Determine TB LAM, Chest X-ray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm1 Extensive TB screening:&#xD;
In this arm, point-of-care tests for TB will be used at randomization (in all patients) and at each scheduled or unscheduled follow-up visit (in patients with signs or symptoms suggestive of TB and no clear alternative diagnosis); TB treatment will only be prescribed to patients with a diagnosis of TB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifampin, isoniazid, pyrazinamide, ethambutol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2: Systematic Empiric treatment (Rifampicin,isoniazid, pyrazinamide, ethambutol) ART&#xD;
In this arm, all patients will start a systematic 6-month TB treatment at randomization. TB screening tests will not systematically be used neither at randomization nor while patients are on TB treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xpert MTB/RIF®, Determine TB LAM, Chest X-ray</intervention_name>
    <description>The following point-of-care TB tests will be systematically performed:&#xD;
Xpert MTB/RIF® on sputum (in all patients able to provide sputum; no sputum induction will be requested in others), Urine LAM (all patients). Depending on clinical presentation, Xpert MTB/RIF® will also be performed on any relevant extra-pulmonary specimen.&#xD;
TB treatment will depend on the result of the tests:&#xD;
Criteria met for confirmed or probable TB : TB treatment will be initiated immediately (Visit 1) followed by ART initiation 2 weeks later (Visit 2); No evidence of confirmed or probable TB: ART will be started immediately (Visit 1).</description>
    <arm_group_label>Xpert MTB/RIF®, Determine TB LAM, Chest X-ray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ART (Atripla, Truvada, Efavirenz, Combivir)</intervention_name>
    <description>ART (TDF-3TC/FTC or AZT-3TC + efavirenz) will be started immediately after randomization in patients not put on TB treatment, and 2 weeks after initiation of TB treatment in others.&#xD;
ART will be initiated 2 weeks after the onset of TB treatment (V2) for Arm 2</description>
    <arm_group_label>Rifampin, isoniazid, pyrazinamide, ethambutol</arm_group_label>
    <arm_group_label>Xpert MTB/RIF®, Determine TB LAM, Chest X-ray</arm_group_label>
    <other_name>ART</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin, isoniazid, pyrazinamide, ethambutol</intervention_name>
    <description>Arm 1: Only patients who meet standardized criteria for TB at inclusion or during follow-up will receive a standard TB treatment (2ERHZ/4RH); Arm 2: • All patients will start a 6-month standard TB treatment (2ERHZ/4RH) at randomization</description>
    <arm_group_label>Rifampin, isoniazid, pyrazinamide, ethambutol</arm_group_label>
    <arm_group_label>Xpert MTB/RIF®, Determine TB LAM, Chest X-ray</arm_group_label>
    <other_name>Systematic Empiric treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years;&#xD;
&#xD;
          -  HIV-1 infection as documented at any time prior to trial entry, as per national&#xD;
             testing procedures;&#xD;
&#xD;
          -  CD4 &lt;100 cells/mm3;&#xD;
&#xD;
          -  No history of antiretroviral drug use (except transient ART for PMTCT);&#xD;
&#xD;
          -  Able to correctly understand the trial and to sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV-2 co-infection;&#xD;
&#xD;
          -  Contra-indication to efavirenz;&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) &gt;5 times the upper&#xD;
             limit of normal;&#xD;
&#xD;
          -  Creatinine clearance &lt;50 ml/min;&#xD;
&#xD;
          -  Overt evidence that TB treatment should be started immediately;&#xD;
&#xD;
          -  History of TB treatment in the past 5 years;&#xD;
&#xD;
          -  Ongoing TB chemoprophylaxis (isoniazid preventive therapy);&#xD;
&#xD;
          -  Any condition that would lead to differ ART initiation (e.g. acute condition requiring&#xD;
             investigations and/or treatment prior to ART initiation);&#xD;
&#xD;
          -  Current pregnancy or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François-Xavier Blanc, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Nantes, Institut du thorax, CHU Nantes, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kouao Médard Serge Domoua, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Pneumologie, CHU de Treichville, Abidjan, Côte d'Ivoire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sihanouk Hospital Center of Hope</name>
      <address>
        <city>Phnom Penh</city>
        <zip>2318</zip>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CePReF Centre de Prise en charge de Recherche et de Formation</name>
      <address>
        <city>Abidjan</city>
        <state>Yopougon</state>
        <zip>1954</zip>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISS ImmunoSuppression Service</name>
      <address>
        <city>Mbarara</city>
        <zip>1956</zip>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pham Ngoc Thach Hospital</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cambodia</country>
    <country>Côte D'Ivoire</country>
    <country>Uganda</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 5, 2014</study_first_submitted>
  <study_first_submitted_qc>February 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2014</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Systematic empiric TB treatment</keyword>
  <keyword>ART</keyword>
  <keyword>TB diagnosis</keyword>
  <keyword>Xpert MTB/RIF®</keyword>
  <keyword>Urine LAM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 22, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT02057796/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

